{"id":"NCT02372799","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)","officialTitle":"A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-28","primaryCompletion":"2018-09-11","completion":"2018-09-11","firstPosted":"2015-02-26","resultsPosted":"2019-10-01","lastUpdate":"2019-10-01"},"enrollment":473,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vilazodone","otherNames":["Viibryd"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Fluoxetine","otherNames":["Prozac"]}],"arms":[{"label":"Vilazodone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Fluoxetine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.","primaryOutcome":{"measure":"Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score","timeFrame":"From Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-20.32,"sd":0.983},{"arm":"Vilazodone","deltaMin":-20.72,"sd":0.977},{"arm":"Fluoxetine","deltaMin":-22.71,"sd":1.32}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7662"},{"comp":"OG000 vs OG002","p":"0.1433"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":60,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":186},"commonTop":["Headache","Nausea","Vomiting","Diarrhoea","Abdominal pain upper"]}}